Novo Nordisk A/S (NVO) Analyst Ratings & Price Targets

Novo Nordisk A/S

NVO · NYSE

Analyst Consensus

Underperform

13 analysts

$43

Current

—

Low

$47

Average

—

High

Average target implies +8.17% versus the current price.

Analyst Ratings Synthesis

The consensus is Underperform, backed by all 13 analysts in the supplied consensus, with a mean target of $47 and no reported low or high target. That leaves the stated target only modestly above the observed $45.16 close, while the dispersion cannot be measured because the endpoints are unavailable. The most and least bullish named analysts are not identified in the evidence. Recent revisions have been negative: Morgan Stanley downgraded Novo Nordisk to Underweight from Equal Weight and is also reported as moving to Sell. The substantive disagreement is whether Novo’s depressed valuation and pediatric semaglutide progress outweigh Eli Lilly’s market-share gains, halted trials and the risk that obesity becomes a less dependable growth engine.

Rating Actions

2 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Morgan Stanley	—	Underweight Downgraded	—	—	Sep 10, 2026	Open the report this row came from
Morgan Stanley	—	Sell Downgraded	—	—	Sep 10, 2026	Open the report this row came from
Weiss Ratings	—	Hold Upgraded from Sell (D+) to Hold (C-)	—	—	Aug 5, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

CANTOR FITZGERA

EXANE BNP PARIB

GUGGENHEIM SEC.

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

MORGAN STANLEY

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

UBS

Symbol: NVO
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: NYSE

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries.

Key Issues

Bullish view

The company remains a major GLP-1 player, and positive semaglutide results in the STEP Young pediatric obesity study support additional patient and indication growth.

Bearish view

The Motley Fool says Novo lost the lead to Eli Lilly, while Morgan Stanley’s bearish case centers on further market-share losses to Lilly and intensifying competitive pressure.

Analyst Consensus

See all

Underperform

13 analysts

$43

Current

—

Low

$47

Average

—

High

Average target implies +8.17% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Abbott LaboratoriesABT · NYSE